Flawed studies informed recommendations against CYP2D6 testing for tamoxifen treatment, new study finds

A recent Mayo Clinic study has found that clinical recommendations discouraging the use of CYP2D6 genetic testing to advise tamoxifen treatment in women with breast cancer should be reconsidered because some of the studies the recommendations were based on had flawed methodology. The article, published in the January issue of the Journal of the National Cancer Institute, found that some … Read More